AI Article Synopsis
- * A 44-year-old male with symptoms of disseminated TB developed acute encephalopathy while being treated with moxifloxacin; after stopping the drug, his symptoms completely resolved.
- * This case highlights the need for healthcare providers to be aware of the potential side effects of moxifloxacin, specifically the risk of encephalopathy in patients receiving anti-tubercular therapy.
Article Abstract
Moxifloxacin is a third-generation fluoroquinolone antibiotic with broad spectrum activity and also used as component of anti-tubercular therapy (ATT). Though frequently prescribed, moxifloxacin induced encephalopathy is uncommonly seen. Here we describe a forty four year old male, with features of disseminated tuberculosis (TB) and suspected case of multi-drug resistance (MDR), who developed acute encephalopathy. Extensive laboratory investigations, neuroimaging of brain, cerebrospinal fluid analysis was unremarkable. On stopping moxifloxacin, which was being administerd as part of ATT for MDR TB, encephalopathy resolved completely, thereby proving it to be a case of moxifloxacin induced encephalopathy. To conclude, by presenting this case, we wish to raise awareness about moxifloxacin induced encephalopathy among healthcare providers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijtb.2020.05.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!